Stephen DAmato - Calmare Therapeutics Chief Medical Officer
| CTTCDelisted Stock | USD 0.0001 0.00 0.00% |
Executive
Dr. Stephen J. DAmato, M.D., is Chief Medical Officer of Calmare Therapeutics Incorporated. He was practicing medicine in Rhode Island for 35 years. Over the past six years, he was the foremost Calmare Pain Therapy Device practitioner with over 1000 patients treated in his medical practice. His efforts with Calmare have established new innovative ways of treating many different chronic pain diagnoses including Chemotherapyinduced Peripheral Neuropathy, Complex Regional Pain Syndrome, Failed Back Surgery Syndrome and Phantom Limb Pain Syndrome. Dr. DAmato will oversee all medical treatment issues and research topics regarding Calmare, globally since 2015.
| Age | 75 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 203-368-6044 |
| Web | http://www.calmaretherapeutics.com |
Calmare Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3785) % which means that it has lost $0.3785 on every $100 spent on assets. This is way below average. Calmare Therapeutics' management efficiency ratios could be used to measure how well Calmare Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ellie Berger | Scholastic | N/A | |
| Stephen Wright | Avis Budget Group | N/A | |
| Sasha Quinton | Scholastic | 46 | |
| William Seward | Vestis | 56 | |
| Brian Choi | Avis Budget Group | 41 | |
| Laurence Respino | U Haul Holding | 63 | |
| Heath Garvin | Scholastic | N/A | |
| Cathleen DeGenova | Avis Budget Group | 62 | |
| Jeffrey Mathews | Scholastic | N/A | |
| Jennifer Settles | U Haul Holding | N/A | |
| MD MBA | U Haul Holding | 46 | |
| Elizabeth Polcari | Scholastic | 64 | |
| Jason Berg | U Haul Holding | 51 | |
| Ravindra Simhambhatla | Avis Budget Group | 55 | |
| Jeffrey Chastain | HE Equipment Services | N/A | |
| Erin Berger | Scholastic | N/A | |
| Peter Rego | Vestis | N/A | |
| Duriya Aziz | Scholastic | N/A | |
| Angela Kervin | Vestis | 49 | |
| Kristine Campbell | U Haul Holding | 48 | |
| Cristina Juvier | Scholastic | N/A | |
Management Performance
| Return On Asset | -0.38 |
Calmare Therapeutics Leadership Team
Elected by the shareholders, the Calmare Therapeutics' board of directors comprises two types of representatives: Calmare Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Calmare. The board's role is to monitor Calmare Therapeutics' management team and ensure that shareholders' interests are well served. Calmare Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Calmare Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Donna Mays, Mang Services | ||
| Conrad Mir, CEO and President and Director | ||
| Thomas MBA, Chief Officer | ||
| Stephen DAmato, Chief Medical Officer | ||
| William Lipford, Division Sales |
Calmare Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Calmare Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.38 | |||
| Operating Margin | (2.14) % | |||
| Current Valuation | 11.54 M | |||
| Shares Outstanding | 30.38 M | |||
| Shares Owned By Institutions | 6.92 % | |||
| Number Of Shares Shorted | 212.63 K | |||
| Price To Earning | (0.68) X | |||
| Price To Sales | 4.82 X | |||
| Revenue | 1.17 M | |||
| Gross Profit | 771.48 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Calmare Stock
If you are still planning to invest in Calmare Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calmare Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |